BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing small molecule oncology drugs. Using structure-based rational drug design, BlossomHill creates new chemical scaffolds to address resistance mutations that limit existing therapies. The company operates an asset-light business model, outsourcing all research and manufacturing to third-party providers. Lead candidate BH-30643 is an oral macrocyclic EGFR inhibitor in Phase 1/2 trials for non-small cell lung cancer (NSCLC). BH-30643 targets multiple oncogenic mutations, including C797S and T790M resistance mutations that emerge after treatment with standard-of-care inhibitors. BlossomHill’s strategy involves seeking accelerated approval for BH-30643 in the C797S-resistant population before expanding into first-line NSCLC. The company is also developing BH-30236, an oral CLK inhibitor in Phase 1 for relapsed leukemia and myelodysplastic syndromes, and BH-501284, a preclinical pan-KRAS inhibitor. BH-30236 targets the CLK-SRSF splicing axis to re-sensitize cancer cells to venetoclax. BlossomHill intends to commercialize its products independently in the U.S. and potentially partner internationally. BlossomHill's leadership previously developed multiple approved cancer therapies using similar macrocyclic design approaches.